Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...
Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...
Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...
Mersana Therapeutics (MRSN) announced the FDA recently granted an additional Fast Track designation to XMT-1660. The new Fast Track ...
The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...
NICE's endorsement of olaparib, produced by AstraZeneca, marks a crucial step forward in the treatment of breast cancer. This ...
Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have ...
Man of Many US on MSN6h
Feel-Good Friday: 10 January – Shot Takers and Spritz MakersIt has been a long, hard first week back in the office, but there is light at the end of the tunnel. Friday has finally ...
A beloved Manchester elementary school principal has lost her battle with cancer, city school officials confirmed. Jenny Lynch, who had been on medical leave from her role as principal at Webster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback